diphenylamine has been researched along with n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 23 (92.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appleby, T; Dadson, C; Hamatake, R; Iverson, C; Lai, C; Larson, G; Maderna, A; Miner, JN; Quart, B; Vernier, JM; Vo, T; Weingarten, P; Yeh, LT | 1 |
| Chang, Q; Chapman, MS; Hedley, DW; Miner, JN | 1 |
| Liu, D; Trink, B; Xing, J; Xing, M | 1 |
| Bedja, D; Chen, Y; Cohn, RD; Dietz, HC; Doyle, JJ; Habashi, JP; Holm, TM; Judge, DP; Kim, D; Lindsay, ME; Loeys, BL; Marugan, JJ; Patnaik, S; Schoenhoff, F; Thomas, CJ; van Erp, C | 1 |
| Liu, Z; Xing, M | 1 |
| Gorges, TM; Krahn, T; Schatz, C; Schiller, J; Schmitz, A; Schuetzmann, D; von Ahsen, O; Zollner, TM | 1 |
| Adjei, AA; Clendeninn, NJ; Dubowy, RL; Dy, GK; Eckhardt, SG; Gore, L; Iverson, C; Jeffers, M; Leffingwell, DP; Lewis, KD; Ma, WW; Miner, JN; Rajagopalan, P; Ramanathan, RK; Sheedy, B; Shen, Z; Von Hoff, DD; Weekes, CD; Weiss, GJ; Yeh, LT | 1 |
| Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K | 1 |
| Capasso, A; Ciardiello, D; Ciardiello, F; Martinelli, E; Morgillo, F; Napolitano, S; Nappi, A; Sforza, V; Troiani, T; Vitagliano, D | 1 |
| Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH | 1 |
| Bartlett, DL; Choudry, HA; Dilly, AK; Guo, ZS; Lee, YJ; Song, X; Zeh, HJ | 1 |
| Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
| Bianco, R; Cardone, C; Ciardiello, D; Ciardiello, F; Fenizia, F; Formisano, L; Lambiase, M; Martinelli, E; Martini, G; Morgillo, F; Napolitano, S; Normanno, N; Troiani, T; Vitagliano, D | 1 |
| Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT | 1 |
| Kiessling, MK; Rogler, G | 1 |
| Bridgewater, J; Cascinu, S; Childs, BH; Dueland, S; Garosi, VL; Giurescu, M; Haas, M; Jassem, J; Martens, UM; Melichar, B; Michl, P; Peeters, M; Rajagopalan, P; Riess, H; Ross, P; Roth, K; Saramak, P; Schmiegel, W; Schulz, A; Seidel, H; Teufel, M; Van Brummelen, D; Van Laethem, JL; Weekes, C; Zaniboni, A | 1 |
| Bryan, JN; Eaton, AM; Henry, CJ; Kim, DY; Kumar, SR; Robinson, KL | 1 |
| Beer, AJ; Braren, R; Esposito, I; Fingerle, A; Gupta, A; Heid, I; Sengkwawoh-Lueong, S; Siveke, JT; Steiger, K; Teichmann, N; Trajkovic-Arsic, M; Wenzel, P; Wörner, C | 1 |
| Cheon, SK; Han, SW; Jang, JE; Kim, HP; Kim, TY; Lim, Y; Park, YL; Song, SH | 1 |
| Blanc, JF; Childs, BH; Choo, SP; Dao, T; Dufour, JF; Gane, EJ; Gérolami, R; Kocsis, J; Krissel, H; Lamlertthon, W; Lim, HY; Llovet, JM; Ma, YT; Mazzaferro, V; Merle, P; Peck-Radosavljevic, M; Reis, D; Ross, P; Roth, K; Ryoo, BY; Sukeepaisarnjaroen, W; Teufel, M; Thongsawat, S; Weiss, KH; Yau, T; Yen, CJ; Yeo, W | 1 |
| Das, M | 1 |
| Goh, KY; Huynh, H; Lee, LY; Mumberg, D; Ong, R; Politz, O; Puehler, F; Scholz, A; Ziegelbauer, K | 1 |
| Jiao, W; Jin, M; Kong, D; Li, H; Lin, P; Liu, Y; Peng, X; Qiu, Y; Wang, R; Zhang, Z; Zhu, S | 1 |
| Belli, V; Ciardiello, D; Ciardiello, F; De Falco, V; Furia, M; Giunta, EF; Kopetz, S; Martinelli, E; Martini, G; Matrone, N; Morgillo, F; Muddassir, AL; Napolitano, S; Sorokin, A; Troiani, T | 1 |
| Mergener, S; Peña-Llopis, S; Siveke, JT | 1 |
2 review(s) available for diphenylamine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2015 |
Targeting the RAS pathway by mitogen-activated protein kinase inhibitors.
Topics: Animals; Azetidines; Benzamides; Benzimidazoles; Diphenylamine; Genes, ras; GTP Phosphohydrolases; Humans; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Mutation; Neoplasms; Niacinamide; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Signal Transduction; Sulfonamides | 2015 |
5 trial(s) available for diphenylamine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cohort Studies; Diphenylamine; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Staging; Neoplasms; Prognosis; Protein Kinase Inhibitors; Sulfonamides; Tissue Distribution; Young Adult | 2013 |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, Hepatocellular; Diphenylamine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2016 |
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diphenylamine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2017 |
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Carcinoma, Hepatocellular; Circulating Tumor DNA; Diphenylamine; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Middle Aged; Mutation; Protein Kinase Inhibitors; ras Proteins; Sorafenib; Sulfonamides; Telomerase; Tumor Suppressor Protein p53 | 2018 |
18 other study(ies) available for diphenylamine and n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
| Article | Year |
|---|---|
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Topics: Administration, Oral; Allosteric Regulation; Animals; Cell Line, Tumor; Diphenylamine; Female; Half-Life; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Sulfonamides | 2009 |
Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Agents; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Diphenylamine; Enzyme Inhibitors; Humans; Male; MAP Kinase Kinase Kinases; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Signal Transduction; Sirolimus; Sulfonamides | 2010 |
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Drug Synergism; Flow Cytometry; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Sirolimus; Sulfonamides; Thyroid Neoplasms; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.
Topics: Animals; Anthracenes; Aorta; Aortic Aneurysm; Diphenylamine; Disease Models, Animal; Disease Progression; Enzyme Activation; Losartan; MAP Kinase Signaling System; Marfan Syndrome; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Protein Kinase Inhibitors; Smad2 Protein; Smad4 Protein; Sulfonamides; Transforming Growth Factor beta | 2011 |
Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Diphenylamine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Iodine Radioisotopes; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Signal Transduction; Sulfonamides; Symporters; Transcriptional Activation; Vorinostat | 2012 |
Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Colorectal Neoplasms; Diphenylamine; DNA; Female; Humans; Kinetics; Male; Mice; Mice, Nude; Real-Time Polymerase Chain Reaction; Reference Standards; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Sulfonamides | 2013 |
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Diphenylamine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Knockdown Techniques; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; RNA Interference; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Humans; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinases; Mucin-2; Neoplasms, Cystic, Mucinous, and Serous; NF-kappa B; Peritoneal Neoplasms; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pseudomyxoma Peritonei; Sulfonamides; Survival Analysis; Transcription Factor AP-1; Xenograft Model Antitumor Assays | 2015 |
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Diphenylamine; Drug Synergism; ErbB Receptors; Female; Humans; Irinotecan; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Diphenylamine; Dog Diseases; Dogs; Down-Regulation; Flow Cytometry; Immunoblotting; Lymphoma, B-Cell; Mitogen-Activated Protein Kinase Kinases; Polymerase Chain Reaction; Programmed Cell Death 1 Receptor; Sulfonamides | 2017 |
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Diffusion Magnetic Resonance Imaging; Diphenylamine; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; MAP Kinase Kinase Kinases; Mice; Neoadjuvant Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Sulfonamides | 2017 |
Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Diphenylamine; Drug Resistance, Neoplasm; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); RNA Interference; RNA, Small Interfering; Sulfonamides | 2018 |
Refametinib in RAS-mutated hepatocellular cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Diphenylamine; Humans; Liver Neoplasms; Mutation; ras Proteins; Sorafenib; Sulfonamides | 2018 |
Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Drug Synergism; Humans; Hypopharyngeal Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Retrospective Studies; Signal Transduction; Sulfonamides | 2019 |
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Cell Line, Tumor; Colorectal Neoplasms; Diphenylamine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Monosomy 3 Is Linked to Resistance to MEK Inhibitors in Uveal Melanoma.
Topics: Cell Line, Tumor; Chromosomes, Human, Pair 3; Diphenylamine; DNA Copy Number Variations; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Monosomy; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Sulfonamides; Survival Analysis; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Uveal Neoplasms | 2021 |